Document is current

Article History

Received: 9 November 2016

Accepted: 19 February 2018

First Online: 2 March 2018

Ethics approval and consent to participate

: This study was approved by the ethics committee of Zhongshan Hospital Fudan University (certification number: 2009–15). Written informed consent was obtained from all the patients involved.The GIDEON study was an international prospective, open-label, multi-centered, non-interventional study of patients with unresectable HCC who had indications for systemic therapy and received sorafenib. All patients met the inclusion and exclusion criteria, were treated with sorafenib at least once. The duration of observation was from the initiation of sorafenib therapy to withdrawal from the study, last follow-up, or death. The GIDEON study protocol [NCT00812175] is available at: ExternalRef removed).

: Not applicable.

: This trial was financially supported by Bayer HealthCare Pharmaceutical Company, Ltd., China.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.